ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.6036
-0.11%
Brent Oil
82.165
-0.34%
Bitcoin
69,978.69
-0.22%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) Noticias

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ALZN
FechaHoraFuenteTítuloSímboloCompañía
16/05/202415:30Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
14/05/202407:00Business WireAlzamend Neuro Announces Initial Closing of Private PlacementNASDAQ:ALZNAlzamend Neuro Inc
13/05/202415:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
10/05/202416:06Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
10/05/202415:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
10/05/202405:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
09/05/202407:00Business WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
07/05/202407:00Business WireAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramNASDAQ:ALZNAlzamend Neuro Inc
15/12/202315:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
11/12/202307:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
20/11/202307:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
16/11/202307:00Business WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
13/11/202307:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
30/10/202307:00Business WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
23/10/202307:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
02/10/202307:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
26/09/202317:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
22/09/202307:00Business WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementNASDAQ:ALZNAlzamend Neuro Inc
01/09/202315:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALZNAlzamend Neuro Inc
30/08/202307:00Business WireAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
24/08/202315:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
10/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALZNAlzamend Neuro Inc
02/08/202315:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALZNAlzamend Neuro Inc
27/07/202315:56Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALZNAlzamend Neuro Inc
22/06/202315:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALZNAlzamend Neuro Inc
22/06/202307:00Business WireAlzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001NASDAQ:ALZNAlzamend Neuro Inc
13/06/202307:00Business WireAlzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare ConferenceNASDAQ:ALZNAlzamend Neuro Inc
04/04/202305:30Business WireAult Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
03/04/202308:35Business WireKILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
03/04/202307:50Business WireAlzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeNASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Su Consulta Reciente

BIT
I09909
IT0005575359 20240603 29.5
EU
BPHBH
BNP Paribas Home Loan Bo...
EU
3274T
3274T
LSE
80CU
Euro.bk.23
GDAX
MUSDUSD
mStable USD
LSE
60ZF
Toy.fa. 22
BIT
S29216
Societe Generale Effekten
LSE
UB02
Ubsetf Jpngba
AMEX
VPC
Virtus Private Credit St...
USOTC
SAABF
SAAB AB (PK)
LSE
49EM
Westpac 33
BTHB
ONITKRW
Onbuff Token
NASDAQ
CHPM
CHP Merger
LSE
0F8R
Malteries Franco Belges
DOWI
DJCIIZT
DJ Commodity Index Zinc TR
NYSE
AQNA
Algonquin Power & Utilit...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados